BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Altor BioScience Corporation 

2810 North Commerce Parkway

Miramar  Florida  33025-3958  U.S.A.
Phone: 954-443-8600 Fax: 954-443-8610


SEARCH JOBS










 Company News
Altor BioScience Corporation Initiates Clinical Development Of Its Novel IL-15 Super Agonist ALT-803 For Relapsed / Refractory Multiple Myeloma Supported By A Newly Awarded Phase 2 SBIR Grant From National Cancer Institute 11/4/2014 10:22:56 AM
Shenzhen Beike Biotechnology Co. Ltd., Altor BioScience Corporation Strike $200 Million Cancer Deal 9/10/2014 10:48:59 AM
Altor BioScience Corporation Awarded SBIR Phase 2 Grant By NCI For Clinical Development Of Its Novel IL-15 Super Agonist For Non-Muscle Invasive Bladder Cancer 8/19/2014 8:48:48 AM
Altor BioScience Corporation Launches Its Proprietary IL-15 Superagonist ALT-803 Into Clinical Trials Against Cancer 8/15/2013 10:49:37 AM
Altor BioScience Corporation and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma 4/30/2012 10:25:23 AM
Florida Biologix(R) Announces Manufacturing Agreement with Altor BioScience Corporation 6/28/2011 11:34:34 AM
Altor BioScience Corporation Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI 5/23/2011 8:37:26 AM
Altor BioScience Corporation Awarded $3 MM SBIR Bridge Grant by National Cancer Institute to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801 9/25/2009 8:05:15 AM
Altor BioScience Corporation Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital 9/10/2008 8:55:20 AM
Altor BioScience Corporation In-Licenses Tissue Factor Antagonists from Genentech, Inc. (DNA) 2/12/2008 8:43:00 AM
12